J&J Stock at All-Time High as UBS Assumes at Buy (JNJ:NYSE)

J&J's run to record highs hasn't reached the finish line yet. Here are the key drivers

Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares still has room to run.

J&J stock at all-time high as UBS assumes at Buy (JNJ:NYSE)

Johnson & Johnson (JNJ) stock hits a record high as UBS assumes its coverage with a Buy ad a $320 target, citing a strong pipeline and growth catalysts. Read more here.

FDA Clears J&J’s IMAAVY as First Drug for Rare Blood Disease

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) secured U.S. Food and Drug Administration approval for IMAAVY to treat warm autoimmune hemolytic anemia in patients 12 and older who …

Johnson & Johnson Shares Jump Toward the Record High After FDA Approval; UBS Lifts Target to $320

Johnson & Johnson's stock reached a record high following FDA approval of its drug Imaavy and a positive sales forecast, despite ongoing legal challenges and market pressures.